Skip to the answer

Letermovir Uses, Dosage, Side Effects and Interactions

Brand name
Prevymis

Prevymis was the first letermovir product the FDA approved, in November 2017. No generic is listed as injections, oral pellets and tablets.

First generic of Prevymis: our estimate, February 2033

Letermovir (Prevymis) is an antiviral medicine used to prevent cytomegalovirus (CMV) infection and disease in certain transplant patients.

Dr. Brian Staiger, PharmD, BCPS
Last reviewed Jul 10, 2026 Content updated Nov 7, 2026 Where our facts come from

Quick links

Ask Anything About LetermovirType a question in your own words. Answered from its FDA label in seconds.

Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.

Letermovir in Short

The Pharmacist’s Take

Dr. Brian Staiger, PharmD, BCPS
Clinical pharmacist Written

Letermovir (Prevymis) is an antiviral that prevents cytomegalovirus (CMV) after a donor stem cell or high-risk kidney transplant by blocking the step where the virus packages its DNA into new copies; on the U.S. market since about 2017 and with no generic listed yet, it has become a standard preventive choice after stem cell transplant. Most people tolerate it well, and it is gentler on blood counts than older CMV antivirals; nausea, diarrhea, vomiting and some leg or ankle swelling are the usual complaints. The real issue is interactions, and a few combinations are never allowed (pimozide, ergot migraine drugs, or simvastatin or pitavastatin taken with cyclosporine).

Key Takeaways From the HelloPharmacist Team

  • Swallow the tablet whole once daily, with or without food, through day 100 after stem cell or day 200 after kidney transplant.
  • Expect closer tacrolimus or sirolimus blood level checks while on letermovir, since it pushes their levels up.
  • Call your care team promptly about unexplained muscle pain or weakness, which can signal muscle breakdown (rhabdomyolysis) from a statin interaction.
  • Avoid St. John's Wort and flag any new seizure medicine or rifampin-type antibiotic, since these can weaken letermovir's protection.

How we write and review this content: our editorial policy

Letermovir by the Numbers

Strengths
5
across 3 forms
Makers and packagers
1
Earliest FDA record
2017
Rank by Medicaid prescriptions
#1,095 of 1,682 drugs
More prescriptions than 34% of the 1,682 drugs we measure
4,462 prescriptions, Q1–Q4 2025
Other forms and routes

Patient Information Guide for Letermovir

What It’s Used For

Prevymis (letermovir) is an antiviral medicine approved to prevent CMV (cytomegalovirus) in specific groups of transplant patients.

  • Stem cell transplant (HSCT) recipients: Prevymis is approved to prevent CMV infection and disease in adults and children 6 months of age and older, weighing at least 6 kg, who received a stem cell transplant from a donor and who themselves carry the CMV virus (CMV-seropositive).
  • Kidney transplant recipients: Prevymis is approved to prevent CMV disease in adults and children 12 years of age and older, weighing at least 40 kg, who received a kidney transplant and are at high risk — meaning the donor tested CMV-positive and the recipient tested CMV-negative (D+/R-).

How It Works

Letermovir works by blocking a viral protein complex called the CMV DNA terminase complex. This complex is essential for the cytomegalovirus to cut and package its DNA into new viral particles. Without this step, the virus cannot make functional copies of itself and spread through the body. Because this target is specific to CMV and not found in human cells, letermovir can attack the virus without using the same mechanism as older antivirals.

Drug Class

Drug Class

  • Cytomegalovirus DNA Terminase Complex Inhibitor
Detailed classifications and sources

The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.

Drug Class

Established Pharmacologic Class (EPC)
  • Cytomegalovirus DNA Terminase Complex Inhibitor

The main drug class the FDA gives it. It is the class named on the drug’s label.

How It Works

Mechanism of action (MoA)
  • Cytochrome P450 2C9 Inducers
  • Cytochrome P450 2C19 Inducers
  • Cytochrome P450 2C8 Inhibitors
  • Organic Anion Transporting Polypeptide 1B1 Inhibitors
  • Organic Anion Transporting Polypeptide 1B3 Inhibitors
  • Cytochrome P450 3A Inhibitors
  • DNA Terminase Complex Inhibitors

What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.

What It Does in the Body

Physiologic effect (PE)

None listed for Letermovir in the FDA’s index.

From our Patient Information GuideLetermovir works by blocking a viral protein complex called the CMV DNA terminase complex. This complex is essential for the cytomegalovirus to cut and package its DNA into new viral particles. Read How Letermovir Works

A change it makes in how the body works.

Chemical Family

Chemical structure (CS)

None listed for Letermovir in the FDA’s index.

The chemical family it belongs to, by its structure.

Drug Family

WHO ATC classification
  • Other antivirals

How the World Health Organization groups it: by the part of the body it acts on and what it treats.

The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.

Dosage

Prevymis is taken once daily, by mouth or by IV infusion, depending on which form your care team prescribes. Tablets can be taken with or without food and must be swallowed whole.

Oral pellets are mixed with soft food or administered through a feeding tube. The IV infusion is given over one hour in a clinical setting and is reserved for patients who cannot take oral medication.

  • For stem cell transplant patients, treatment is typically started between the day of transplant and Day 28, and continued through Day 100 — or up to Day 200 for those at higher risk of late CMV reactivation.
  • For kidney transplant patients, treatment starts between Day 0 and Day 7 after transplant and continues through Day 200.
  • If you also take cyclosporine, your dose of Prevymis will be adjusted — do not change your dose on your own.

Typical Doses

Your prescriber chooses your dose, so take it exactly as prescribed.

Letermovir Taken by Mouth

Preventing CMV infection after a stem cell transplant
Adults and children 12 years and older weighing at least 30 kg Usual dose 480 mg once a day
  • 480 mg once daily orally (one 480 mg tablet or two 240 mg tablets
  • Four 120 mg packets of oral pellets for patients who cannot swallow tablets) through 100 days post-HSCT

Good to know

May be continued through Day 200 post-HSCT in patients at risk for late CMV infection and disease; initiate between Day 0 and Day 28 post-HSCT

HSCT stands for hematopoietic stem cell transplant.

Children weighing 30 kg and above Usual dose 480 mg once a day
  • 480 mg once daily: one 480 mg tablet or two 240 mg tablets
  • Or four 120 mg packets of oral pellets
Children 15 kg to less than 30 kg Usual dose 240 mg once a day
  • 240 mg once daily: one 240 mg tablet or two 120 mg packets of oral pellets
Children 7.5 kg to less than 15 kg Usual dose 120 mg once a day
  • 120 mg once daily: one 120 mg packet of oral pellets (tablets not recommended)
Children 6 kg to less than 7.5 kg Usual dose 80 mg once a day
  • 80 mg once daily: four 20 mg packets of oral pellets (tablets not recommended)
Children 30 kg and above also taking cyclosporine Usual dose 240 mg once a day
  • 240 mg once daily: one 240 mg tablet or two 120 mg packets of oral pellets

Good to know

Co-administered with cyclosporine

Children 15 kg to less than 30 kg also taking cyclosporine Usual dose 120 mg once a day
  • 120 mg once daily: one 120 mg packet of oral pellets (tablets not recommended)

Good to know

Co-administered with cyclosporine

Children 7.5 kg to less than 15 kg also taking cyclosporine Usual dose 60 mg once a day
  • 60 mg once daily: three 20 mg packets of oral pellets (tablets not recommended)

Good to know

Co-administered with cyclosporine

Children 6 kg to less than 7.5 kg also taking cyclosporine Usual dose 40 mg once a day
  • 40 mg once daily: two 20 mg packets of oral pellets (tablets not recommended)

Good to know

Co-administered with cyclosporine

Preventing CMV disease after a kidney transplant
For adults and children 12 years and older weighing at least 40 kg
Usual dose 480 mg once a day
  • 480 mg once daily orally (one 480 mg tablet or two 240 mg tablets
  • Four 120 mg packets of oral pellets for patients who cannot swallow tablets) through 200 days post-transplant

Good to know

Initiate between Day 0 and Day 7 post-transplant

Adults and pediatric patients 12 years and older (HSCT at least 30 kg or kidney transplant at least 40 kg) taking cyclosporine
For adults and children 12 years and older also taking cyclosporine
Usual dose 240 mg once a day

Good to know

If cyclosporine is started later, next dose is 240 mg once daily; if stopped, next dose is 480 mg once daily

HSCT stands for hematopoietic stem cell transplant.

See the Full Dosing Instructions on DailyMed →

Letermovir Injection

Preventing CMV infection after a stem cell transplant
Adults and children 12 years and older weighing at least 30 kg Usual dose 480 mg once a day
  • 480 mg once daily as an IV infusion over 1 hour through 100 days post-HSCT

Good to know

May be continued through Day 200 post-HSCT in patients at risk for late CMV infection

HSCT stands for hematopoietic stem cell transplant.

IV means given into a vein (intravenous).

Children 30 kg and above Usual dose 480 mg once a day
  • 480 mg once daily IV

IV means given into a vein (intravenous).

Children 15 kg to less than 30 kg Usual dose 120 mg once a day
  • 120 mg once daily IV

IV means given into a vein (intravenous).

Children 7.5 kg to less than 15 kg Usual dose 60 mg once a day
  • 60 mg once daily IV

IV means given into a vein (intravenous).

Children 6 kg to less than 7.5 kg Usual dose 40 mg once a day
  • 40 mg once daily IV

IV means given into a vein (intravenous).

Preventing CMV disease after a kidney transplant
For adults and children 12 years and older weighing at least 40 kg
Usual dose 480 mg once a day
  • 480 mg once daily as an IV infusion over 1 hour through 200 days post-transplant

IV means given into a vein (intravenous).

Injection with cyclosporine
For adults and children 12 years and older also taking cyclosporine
Usual dose 240 mg once a day

Good to know

Co-administered with cyclosporine

See the Full Dosing Instructions on DailyMed →

Side Effects

The most commonly reported side effects during clinical trials include:

Common side effects

  • Nausea
  • Diarrhea
  • Vomiting
  • Swelling in the legs or feet (peripheral edema)
  • Cough
  • Headache
  • Fatigue
  • Abdominal pain

When to get medical help

  • Call your doctor if you notice signs of a serious drug interaction — such as unusual muscle pain or weakness, which could signal a rare but dangerous condition called rhabdomyolysis (muscle breakdown)
  • Tell your doctor right away if you experience an allergic reaction, such as difficulty breathing, rash, or swelling
  • If you receive the IV form and have kidney problems, report any decrease in urine output or signs of worsening kidney function to your care team
  • Tell your doctor about any new or worsening heart symptoms, such as rapid or irregular heartbeat
  • Contact your care team if you experience any hearing changes, especially if receiving the IV form

A higher rate of cardiac events such as rapid heartbeat (tachycardia) and atrial fibrillation was seen in Prevymis-treated stem cell transplant patients compared to placebo — though most were mild to moderate. Let your care team know right away if you experience a fast or irregular heartbeat, difficulty breathing, severe allergic reaction, or unusual muscle pain or weakness.

Warnings and Precautions

  • Drug interactions are the biggest concern. Prevymis affects and is affected by many medications commonly used in transplant care. Some combinations are prohibited entirely (pimozide, ergot alkaloids, and certain statins with cyclosporine). Others require close monitoring or dose changes. Your full medication list must be reviewed before and throughout treatment.
  • IV form contains hydroxypropyl betadex. This inactive ingredient can accumulate in patients with reduced kidney function. Animal studies have shown it may affect hearing. The IV form should only be used when oral treatment is not possible, and for no longer than 4 weeks if avoidable. Kidney function should be monitored closely in patients with significant renal impairment using the IV form.
  • Severe liver disease: Prevymis is not recommended for patients with severe hepatic (liver) impairment.

Interactions

Prevymis has a wide range of significant drug interactions — always share your full medication list with your prescriber and pharmacist before starting.

  • Pimozide: Contraindicated — Prevymis raises pimozide levels, risking dangerous heart rhythm problems (QT prolongation, torsades de pointes).
  • Ergot alkaloids (ergotamine, dihydroergotamine): Contraindicated — Prevymis raises their levels, risking ergotism (severe, dangerous blood vessel spasm).
  • Pitavastatin and simvastatin + cyclosporine: Contraindicated — the combination dramatically raises statin levels, risking serious muscle damage (myopathy or rhabdomyolysis).
  • Cyclosporine: Raises letermovir levels significantly; a lower Prevymis dose is required when these are taken together.
  • Other statins (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin): Prevymis increases their levels; dose limits or reductions apply; monitor for muscle pain.
  • Tacrolimus and sirolimus (transplant immunosuppressants): Prevymis raises blood levels; frequent monitoring and dose adjustment of these drugs are needed.
  • Warfarin: Prevymis lowers warfarin levels; monitor INR closely to maintain anticoagulation.
  • Carbamazepine, phenobarbital, phenytoin, rifampin, rifabutin, nafcillin, St. John's Wort, efavirenz, etravirine, nevirapine, bosentan, modafinil, thioridazine: These can reduce Prevymis levels, potentially making it less effective; co-use is generally not recommended.
  • Antidiabetic agents (glyburide, repaglinide, rosiglitazone): Prevymis may raise their levels; monitor blood glucose closely.
  • Proton pump inhibitors (omeprazole, pantoprazole): Prevymis may lower their levels; clinical monitoring may be needed.

Interactions Listed in the FDA-Approved Label

From the Letermovir prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • What happensIncreases cyclosporine and letermovir concentrations.
    What to doDecrease PREVYMIS to 240 mg once daily in patients 12 years and older; frequently monitor cyclosporine whole blood concentrations.
  • What happensIncreases pimozide; risk of QT prolongation and torsades de pointes.
    What to doCo-administration is contraindicated.
  • Ergotamine, dihydroergotamine
    What happensIncreases ergot alkaloid concentrations; risk of ergotism.
    What to doCo-administration is contraindicated.
  • Pitavastatin, simvastatin
    What happensIncreases HMG-CoA reductase inhibitor concentrations.
    What to doNot recommended; contraindicated with cyclosporine.
  • What happensIncreases atorvastatin concentrations.
    What to doDo not exceed atorvastatin 20 mg daily; monitor for myopathy and rhabdomyolysis; not recommended with cyclosporine.
  • Rifampin, rifabutin
    What happensDecreases letermovir concentrations.
    What to doCo-administration is not recommended due to potential loss of efficacy.
  • Carbamazepine, phenobarbital, phenytoin
    What happensDecreases letermovir concentrations.
    What to doCo-administration is not recommended due to potential loss of efficacy.
  • St. John's wort
    What happensDecreases letermovir concentrations.
    What to doCo-administration is not recommended due to potential loss of efficacy.
  • What happensDecreases warfarin concentrations.
    What to doFrequently monitor INR.
  • Tacrolimus, sirolimus
    What happensIncreases tacrolimus or sirolimus concentrations.
    What to doFrequently monitor whole blood concentrations during and after PREVYMIS and adjust the dose.
Read the label’s full interactions text

7 DRUG INTERACTIONS Dosage Adjustment: If PREVYMIS is co-administered with cyclosporine, the dosage of PREVYMIS should be decreased to 240 mg once daily in adult and pediatric patients 12 years of age and older. If PREVYMIS is co-administered with cyclosporine in pediatric patients less than 12 years of age, dose adjustment may be required. Co-administration of PREVYMIS may alter the plasma concentrations of other drugs and other drugs may alter the plasma concentrations of PREVYMIS. Consult the full prescribing information prior to and during treatment for potential drug interactions. 7.1 Potential for Other Drugs to Affect PREVYMIS Letermovir is a substrate of organic anion-transporting polypeptide 1B1/3 (OATP1B1/3) and P-glycoprotein (P-gp) transporters and UDP-glucuronosyltransferase 1A1/3 (UGT1A1/3) enzymes. Co-administration of PREVYMIS with drugs that are inhibitors of OATP1B1/3 transporters may result in increases in letermovir plasma concentrations (Table 11). Co-administration of PREVYMIS with inducers of transporters (e.g., P-gp) and/or enzymes (e.g., UGTs) is not recommended due to the potential for a decrease in letermovir plasma concentrations (see Table 11 ). 7.2 Potential for PREVYMIS to Affect Other Drugs Co-administration of PREVYMIS with midazolam results in increased midazolam plasma concentrations, indicating that letermovir is a moderate inhibitor of CYP3A. Co-administration of PREVYMIS with drugs that are CYP3A substrates may result in clinically relevant increases in the plasma concentrations of co-administered CYP3A substrates (Table 11). Letermovir is an inhibitor of OATP1B1/3 transporters.

Excerpted: the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

Before You Start

  • Current medications: Tell your prescriber about every drug, supplement, and herbal product you take — the interaction list for Prevymis is long and includes common transplant medications.
  • Kidney problems: If you have reduced kidney function and will use the IV form, your care team must monitor your kidney function closely due to buildup of the IV vehicle (hydroxypropyl betadex).
  • Liver problems: Prevymis is not recommended for patients with severe hepatic impairment (Child-Pugh Class C). No dose adjustment is needed for mild or moderate liver disease.
  • Pregnancy: Animal studies showed potential harm to fetuses; the risk to human pregnancies is not fully known. Discuss with your doctor if you are pregnant or planning to become pregnant.
  • Breastfeeding: It is not known if letermovir passes into human breast milk. Weigh the benefits of breastfeeding against potential risks with your doctor.
  • Children: Prevymis is approved for stem cell transplant recipients as young as 6 months (weighing at least 6 kg), but is not established for kidney transplant patients under 12 years old or under 40 kg.
  • Older adults: No dose adjustment is needed based on age alone; safety and efficacy were similar across age groups in clinical trials.

Overdose

There is no specific antidote for a Prevymis overdose. If too much is taken, medical staff will monitor for side effects and provide supportive treatment as needed. It is not known whether dialysis can meaningfully remove letermovir from the body.

Half-Life and How Your Body Processes It

After an oral dose, letermovir is absorbed relatively quickly, with peak blood levels reached within about 1.5 to 3 hours. Food does not meaningfully change the total amount absorbed (though it can modestly increase the peak level), so tablets can be taken with or without a meal. Letermovir is very heavily bound to proteins in the blood (about 99%) and is eliminated primarily through the liver; about 93% of a dose leaves the body through the feces. The drug has a half-life of roughly 12 hours, and steady blood levels are reached after about 9 to 10 days. Oral bioavailability (how much of the drug reaches the bloodstream) varies by patient population and whether cyclosporine is used at the same time — cyclosporine significantly increases letermovir exposure, which is why a dose adjustment is required.

Storage

Store PREVYMIS tablets in the original package until use to protect from moisture. Store PREVYMIS tablets at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) .

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Letermovir: Pharmacist Answers to Common Questions

Quick, plain-English answers to the questions patients ask most about Letermovir — the kind of thing our pharmacy team would talk through with you at the counter.

What exactly is Prevymis being used for in my situation?

Prevymis is an antiviral medicine prescribed to prevent a virus called CMV — cytomegalovirus — from activating after your transplant. Many people carry CMV without any symptoms, but after a transplant, when your immune system is suppressed, the virus can reactivate and cause serious illness. Prevymis works by blocking the virus from making copies of itself before it can cause disease.

Can I take my tablet with food, or does it need to be on an empty stomach?

Good news — you can take your Prevymis tablet with or without food, so there's no need to time it around meals. Just try to take it at the same time each day to keep your levels consistent. If you're using the oral pellets, those get mixed into soft food, so eating is part of how you take them.

What side effects should I expect, and when should I call my doctor?

The most common side effects are nausea, diarrhea, vomiting, swelling in the feet or legs, cough, headache, fatigue, and stomach pain. These are generally manageable, and most people who stopped the drug in studies did so because of nausea. That said, call your doctor right away if you notice a fast or irregular heartbeat, severe difficulty breathing, signs of an allergic reaction, or unusual muscle pain or weakness — those need to be checked out promptly.

I'm on several other medications for my transplant. Is that a problem with Prevymis?

Drug interactions are probably the most important thing to know about Prevymis. It can raise the blood levels of several common transplant drugs — including tacrolimus, sirolimus, and cyclosporine — which means your care team will likely need to check those levels more often and possibly adjust those doses. Some combinations are completely off-limits, like pimozide or ergot-based migraine medicines. Always make sure every member of your care team has your full medication list, including any supplements or herbal products like St. John's Wort.

I'm getting the IV form in the hospital. Is that the same as the pill?

The IV form delivers letermovir directly into your bloodstream and is used when you can't take anything by mouth. The IV version contains an inactive ingredient called hydroxypropyl betadex, which can build up if your kidneys aren't working well, so your kidney function will be monitored. As soon as you're able to swallow, your team will switch you to the oral form — the goal is to use the IV version for as short a time as possible.

Is Prevymis safe during pregnancy?

There's no solid human data yet on whether Prevymis is safe during pregnancy. Animal studies did show potential harm to developing fetuses at higher doses. If you're pregnant, planning to become pregnant, or breastfeeding, it's really important to have that conversation with your doctor so you can weigh the risks and benefits for your specific situation. Don't stop any prescribed medication on your own without talking to your care team first.

Is letermovir available over the counter?

No. Letermovir is a prescription medicine: every letermovir product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was letermovir first available?

The earliest FDA record we hold for letermovir is from 2017: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when letermovir was first used.

What is the brand name of letermovir?

Letermovir is the generic name. Its brand name is Prevymis.

What is the generic name of Prevymis?

The generic name of Prevymis is letermovir. A generic name is the name of the active ingredient, the same whichever company makes the medicine; a brand name belongs to one company. Your prescription label may show either name.

What drug class is letermovir?

Letermovir belongs to the drug class Cytomegalovirus DNA Terminase Complex Inhibitor, its established pharmacologic class on the FDA label. The FDA also groups it by how it works: CYP2C9 Enzyme Inducer, CYP2C19 Enzyme Inducer and CYP2C8 Enzyme Inhibitor.

What strengths does letermovir come in?

Letermovir is listed in the FDA's National Drug Code Directory in these forms and strengths. Injection (into a vein): 20 mg/mL. Oral pellets (by mouth): 20 mg and 120 mg. Tablet (by mouth): 240 mg and 480 mg. A listing does not mean every pharmacy stocks every strength.

How much does letermovir cost?

What you pay depends on your insurance, your pharmacy and the strength you take. As a benchmark, state Medicaid programs paid an average of $270.21 to $270.60 per tablet of brand-name Prevymis across 2 strengths over the four quarters through Q1 2026 (CMS's State Drug Utilization Data), before the rebates drug makers pay Medicaid. CMS's weekly pharmacy survey (NADAC) has no price for it, and Medicaid's figure is what a program paid, not the price at the counter. No national price was found for letermovir injections or oral pellets. The pharmacy prices section of this page lists every strength priced.

Is there a letermovir shortage?

No. Letermovir is not on the FDA's drug shortage list as of Nov 22, 2026. A single pharmacy can still run short for a while without a national shortage, and your pharmacist can tell you what they are seeing.

Where can I read the letermovir prescribing information (package insert)?

The full FDA-approved prescribing information for letermovir, also called the package insert or drug label, is published on DailyMed, the National Library of Medicine's library of FDA labels. Each company's version has its own label; this page is built from Merck Sharp & Dohme LLC's, revised Jan 14, 2026, and links to it on DailyMed.

Can you crush letermovir?

Some forms of letermovir are on our Do Not Crush list of tablets and capsules that should not be crushed or chewed: letermovir (tablet); Prevymis (tablet). They are listed for a reason such as irritation, a bad taste or a special formulation. A form that is not on the list may still come with its own instructions, so check the label and ask your pharmacist before you crush, split or open any medicine. Each listed form’s reason and instructions are on our Do Not Crush list.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Ask Anything About Letermovir

Skip the scrolling. Ask in your own words and get an answer from Letermovir’s FDA label and our pharmacists’ own work.

Try:

Name another drug or a supplement in your question and we check both.

AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
  • Sources: Letermovir’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
  • Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
  • Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
  • Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.

More About Letermovir on HelloPharmacist

Still have a question? A licensed pharmacist answers for free, as soon as they can.
Detailed Data & References for Letermovir Forms and strengths, pricing, billing codes, manufacturers, safety reports and sourcing: the data behind the page. Most people can stop here. Each section below opens on a tap.

Letermovir Forms and Strengths (How It Comes)

Letermovir comes in 3 dose forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Letermovir inactive ingredients by manufacturer.

Injection

Into a vein
Brands Prevymis (the first brand, 2017)
How this form is used
What it may be used for
  • Prevymis injection is used to help prevent cytomegalovirus (CMV) infection and disease in certain stem cell transplant recipients and high-risk kidney transplant recipients.
  • Prevymis injection is meant only for people who cannot take oral therapy.
Important instructions
  • Prevymis injection must be diluted before it is given, and it is given through a sterile in-line filter.
  • Prevymis injection is given as an infusion into a vein at a constant rate over 1 hour, once daily. It is not given as a quick bolus injection.
  • Prevymis injection users are switched to oral Prevymis as soon as they can take medicine by mouth. If possible, intravenous use should not go beyond 4 weeks.
  • Prevymis injection should not be used with IV bags or infusion sets that contain the plasticizer DEHP.
Available strengths 1 strength
2 FDA-listed product records ⓘ

Oral pellets

By mouth
Brands Prevymis (the first brand, 2017)
How this form is used
What it may be used for
  • Prevymis oral pellets are used to help prevent CMV infection and disease in certain stem cell transplant recipients and high-risk kidney transplant recipients.
  • Prevymis oral pellets can be used for people who cannot swallow tablets, and are an option for some young children based on their weight.
Important instructions
  • Prevymis oral pellets are given by mouth mixed with soft food, or through a nasogastric or gastric feeding tube.
  • Prevymis oral pellets should not be crushed or chewed.
  • Prevymis oral pellets are taken once daily, using one or more packets as directed by the prescriber. Follow the Instructions for Use for preparing them.
Available strengths 2 strengths
2 FDA-listed product records ⓘ

Tablet

By mouth
Brands Prevymis (the first brand, 2017)
How this form is used
What it may be used for
  • Prevymis tablets are used to help prevent CMV infection and disease in certain stem cell transplant recipients and high-risk kidney transplant recipients.
Important instructions
  • Prevymis tablets are taken by mouth once daily, with or without food.
  • Prevymis tablets should be swallowed whole.
  • Prevymis tablets are not recommended for some smaller children based on their weight; the prescriber chooses the right form.
Available strengths 2 strengths
2 FDA-listed product records ⓘ

Letermovir on the U.S. Market: Products, Makers and Brands

How Letermovir appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

1 company lists 6 Letermovir product records with the FDA, mostly as injection, oral pellets, tablet; the earliest marketing or approval year on record is 2017. The one brand name in the directory today is Prevymis; the rest are generics.

3
Dose forms ⓘ
1
Labelers (makers, repackagers, distributors)
1
Brand names ⓘ
6
FDA-listed product records ⓘ
2017
Earliest FDA record ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Powder (3) · Unfinished tablet, film coated (2) · Unfinished injection, powder, for solution (1) · Unfinished injection, solution (1) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.

How Widely Letermovir Is Used (Medicaid Data)

How many Letermovir prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.

4,462
Medicaid prescriptions filled (Q1–Q4 2025)
$34.3M paid by Medicaid, before rebates

How commonly is Letermovir prescribed? Of the 1,682 medications we measure, Letermovir ranks #1,095 by Medicaid prescriptions — more than 35% of them.

Where Letermovir ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5

Utilization by Letermovir product

Pick a strength and form to see its own numbers. Brand and generic versions are counted together.

The 480 mg oral tablet is the most-dispensed Letermovir product — about 96% of these Medicaid prescriptions.

letermovir 480 MG Oral Tablet Most dispensed

4,279 Medicaid prescriptions (Q1–Q4 2025) 96% of Letermovir prescriptions shown $33.1M paid by Medicaid, before rebates ≈ $7,729 per prescription, before rebates

2 of 5 listed NDCs had Medicaid claims. RxNorm 1988673

letermovir 240 MG Oral Tablet

140 Medicaid prescriptions (Q1–Q4 2025) 3% of Letermovir prescriptions shown $1.1M paid by Medicaid, before rebates ≈ $7,788 per prescription, before rebates

2 of 5 listed NDCs had Medicaid claims. RxNorm 1988666

letermovir 120 MG Oral Pellet

43 Medicaid prescriptions (Q1–Q4 2025) <1% of Letermovir prescriptions shown $168,934 paid by Medicaid, before rebates ≈ $3,929 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 2693191

Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.

Source: Medicaid State Drug Utilization Data (CMS), all states. 5 of the 12 listed Letermovir NDCs had Medicaid claims.

Compare Letermovir Products

A representative set of FDA-listed product records for Letermovir — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Strength Route Manufacturer / Labeler Category ⓘ Details
💊Injection
20 mg/mL Intravenous Merck Sharp & Dohme LLC × 2 listings NDA View NDC →
💊Oral pellets
20 mg Oral Merck Sharp & Dohme LLC NDA View NDC →
120 mg Oral Merck Sharp & Dohme LLC NDA View NDC →
💊Tablet
240 mg Oral Merck Sharp & Dohme LLC NDA View NDC →
480 mg Oral Merck Sharp & Dohme LLC NDA View NDC →

Showing 6 of 6 products — FDA National Drug Code Directory. See every product, package size and price: browse all 6 Letermovir NDCs →

Letermovir Recall History

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Letermovir recalls since July 2021.

✅No Letermovir recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.

Letermovir in RxNorm: From Ingredient to Every Form and Strength

RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.

Dose forms
3
Strengths
6
Forms in current FDA listings
3 of 3
In current FDA listings No current FDA listing
Ingredient (IN) Letermovir RxCUI 1988648
  1. Dose form (SCDF) Injection RxCUI 1988651
    In current FDA listings
    Its 2 strengths (SCD)
  2. Dose form (SCDF) Oral Pellet RxCUI 2693184
    In current FDA listings
    Its 2 strengths (SCD)
  3. Dose form (SCDF) Oral Tablet RxCUI 1988665
    In current FDA listings
    Its 2 strengths (SCD)

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

What Medicaid Pays for Letermovir

CMS’s weekly pharmacy survey (NADAC) has no price for Letermovir, so here is what state Medicaid programs paid for it over the four quarters through Q1 2026, before rebates. It is not your price at the counter.

No price was found for Letermovir injections or oral pellets, so the prices below are for the tablets only.

FormStrengthVersion What Medicaid paid
Tablet · Oral 240 mg Prevymis (brand) $270.21 per tablet NDC details & Medicaid use
Tablet · Oral 480 mg Prevymis (brand) $270.60 per tablet NDC details & Medicaid use
Why it helps: it shows whether the drug itself is cheap or costly, and whether a cash price you are quoted is in a reasonable range. What you pay also depends on your insurance and pharmacy.

Source: CMS State Drug Utilization Data, total paid divided by units paid for across every state, for each strength’s packages.

Letermovir Brand Names

Letermovir has one brand name on record: Prevymis. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.

Prevymis the first brand, 2017

Who Makes Letermovir: Manufacturers and Labelers

One company lists Letermovir products with the FDA. By number of product records, the largest are Merck Sharp & Dohme LLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Merck Sharp & Dohme LLC 6

Sources for This Letermovir Page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. Prescribing information dated Jan 14, 2026, the label version this page reads. A label changes when the FDA approves new uses, doses or warnings, so this is not the day the page itself last changed. Read the full label on DailyMed
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Letermovir.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.

Where this information comes from

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source.

Clinical labels in scope
1
Finished products in the current FDA directory
6
Companies listing them (makers, repackagers, distributors)
1
FDA labeler codes behind them ⓘ
1
Linked representative label ⓘ
Merck Sharp & Dohme LLC
Linked label effective
Jan 14, 2026
Composite sections available
23
Linked SPL Set ID
1b49df80-be4f-47e0-a0b7-123f3e69395b
Linked SPL Document ID
282d792e-e2f2-4744-8526-4d18427c55cb
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Merck Sharp & Dohme LLC is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →